Bivalirudin

證據等級: L5

預測適應症: 0 個

Bivalirudin: No Repurposing Candidates Identified by TxGNN

One-Sentence Summary

Bivalirudin is a synthetic direct thrombin inhibitor (DTI) used as an anticoagulant, best known for its use during percutaneous coronary intervention (PCI) and in patients with, or at risk of, heparin-induced thrombocytopenia (HIT). The current TxGNN analysis did not generate any repurposing predictions for this compound. This evaluation is incomplete due to two critical data gaps — missing MOA data and absent Danish regulatory records — and a repurposing recommendation cannot be issued at this stage.

Quick Overview

Item	Content
Original Indication	Anticoagulation during PCI; heparin-induced thrombocytopenia (based on established pharmacological knowledge; no formal indication text retrieved from the Evidence Pack)
Predicted New Indication	None identified
TxGNN Prediction Score	Not available
Evidence Level	Not evaluated
Denmark Market Status	Not marketed (0 authorisations on record)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why No Prediction Was Generated

Bivalirudin (DrugBank ID: DB00006) is a 20-amino-acid synthetic peptide that reversibly and directly inhibits thrombin — both free and clot-bound — by binding simultaneously to the active catalytic site and the anion-binding exosite I. This bivalent binding profile distinguishes it from heparin and is the basis of its anticoagulant use in cardiovascular settings.

Despite this well-characterised pharmacological profile, the TxGNN knowledge-graph pipeline returned no repurposing candidates in this run. Two factors are likely responsible:

Missing MOA data in the Evidence Pack. The original_moa field is marked as a data gap (severity: High). Without a structured mechanism-of-action record linked to the knowledge graph, TxGNN’s graph-traversal and disease-similarity modules cannot anchor the drug to downstream biological targets and pathways that would otherwise surface novel indications.
No Danish regulatory linkage. The Evidence Pack contains zero approved indications and zero marketing authorisations for Denmark. The drug-indication edges that ordinarily seed TxGNN’s scoring are therefore absent, which further constrains prediction coverage.

Note: Bivalirudin is centrally authorised in Europe under the brand name Angiox (EMA/H/C/000562). The absence of Danish national records in this Evidence Pack may reflect a data-collection gap rather than a genuine lack of availability. This should be verified against the EMA product database and the Danish Medicines Agency (Lægemiddelstyrelsen) register before concluding that the product is truly unavailable in Denmark.

Safety Considerations

All safety fields (key warnings, contraindications, drug–drug interactions) are absent from the current Evidence Pack.

Please refer to the approved Summary of Product Characteristics (SmPC) for Angiox — available via the EMA product page — for full safety information, including bleeding risk, renal dose adjustments, and interactions with other anticoagulants or antiplatelets.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model produced no repurposing predictions for Bivalirudin in this evaluation cycle, and two blocking or high-severity data gaps prevent a meaningful mechanistic or regulatory assessment from being completed. No evidence review can be performed without a target indication to anchor it.

To proceed, the following is needed:

Resolve DG002 (High) — MOA data: Query the DrugBank API for DB00006 to retrieve structured mechanism-of-action, target, and pathway data. This is essential for TxGNN graph-based scoring and for the mechanistic rationale section.
Resolve DG001 (Blocking) — Danish regulatory / SmPC data: Cross-check the EMA centralised authorisation database and Lægemiddelstyrelsen product register for Bivalirudin / Angiox. Download the current SmPC PDF to extract approved indications, warnings, and contraindications.
Re-run TxGNN pipeline: Once the MOA and indication data are populated, re-execute the knowledge-graph prediction step. With bivalent thrombin inhibition as the core mechanism, candidate indications in thrombotic, inflammatory, or complement-pathway disorders may emerge.
Verify Denmark market availability: Confirm whether Angiox is commercially available via EMA centralised authorisation and whether it is reimbursed under the Danish national formulary, independent of a national MA number.

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.